MetaCap

Evaxion A/S (EVAX) vs INmune Bio (INMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

INmune Bio (INMB) has outperformed Evaxion A/S (EVAX) over the past year, losing 45.2% versus a loss of 56.6%. Over five years, INMB leads with a -93.8% price change compared with -99.1% for EVAX. INmune Bio is the larger company by market cap ($25.6 million vs $20.8 million), about 1.2 times the size.

Evaxion A/S converts more of its revenue into profit, with a net margin of -102.4% versus -91866.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVAX-56.56%INMB-45.23%
+73%+3%-67%
Nov 21, 20251 yearNov 20, 2026
EVAX-99.19%INMB-93.81%
+10%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVAX versus INMB key metrics
MetricEVAXINMB
Share price$2.25$0.827
Market cap$20.75M$25.60M
1-day change+10.84%-7.50%
YTD return-52.83%-46.99%
1-year return-56.56%-45.23%
5-year return-99.07%-93.80%
EPS (TTM)$-1.00$-0.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.53M$50.00K
Revenue growth (YoY)+125.12%+257.14%
Net income (latest FY)$-7.71M$-45.93M
Operating margin-122.66%-94766.00%
Net margin-102.38%-91866.00%
52-week high$6.92$2.60
52-week low$2.03$0.8189
Distance from 52-week high-67.49%-68.19%
Analyst consensusnonestrong_buy
Avg. price target upside+400.00%+746.43%
Average volume85.00K338.47K
Shares outstanding9.22M30.96M
Employees4621
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INMB has outperformed EVAX by 11.3 percentage points over the past year.
  • Evaxion A/S is more profitable, keeping -102.4 cents of every revenue dollar as net income versus -91866.0 cents for INmune Bio.
  • INmune Bio grew revenue faster in its latest fiscal year (+257.14% vs +125.12%).

About Evaxion A/S

EVAX stock →

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees

About INmune Bio

INMB stock →

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

EVAX vs INMB FAQ

Which is bigger, Evaxion A/S or INmune Bio?

INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $20.75M for Evaxion A/S (EVAX).

Which stock has performed better over the past year, EVAX or INMB?

INMB returned -45.23% over the past 12 months, compared with -56.56% for EVAX (price return, excluding dividends). Past performance does not predict future results.

Are Evaxion A/S and INmune Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons